Cargando…

Immunotherapy and Hepatocellular Cancer: Where Are We Now?

SIMPLE SUMMARY: HCC is the third-leading cause of cancer death worldwide. Prior to the immunotherapy era, treatment of advanced HCC was dominated by antiangiogenic tyrosine kinase inhibitors, with a quite poor prognosis with a median survival time of around one year. In this review, we aimed to elab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valery, Marine, Cervantes, Baptiste, Samaha, Ramy, Gelli, Maximiliano, Smolenschi, Cristina, Fuerea, Alina, Tselikas, Lambros, Klotz-Prieux, Caroline, Hollebecque, Antoine, Boige, Valérie, Ducreux, Michel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497386/ https://www.ncbi.nlm.nih.gov/pubmed/36139683 http://dx.doi.org/10.3390/cancers14184523

Ejemplares similares

Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments
por: Valery, Marine, et al.
Publicado: (2023)

Precision Medicine in Pancreatic Ductal Adenocarcinoma: The Impact of Targeted Therapies on Survival of Patients Harboring Actionable Mutations
por: Tarabay, Anthony, et al.
Publicado: (2023)

Molecular targeted therapy of BRAF-mutant colorectal cancer
por: Ducreux, Michel, et al.
Publicado: (2019)

Immunotherapy in Advanced Biliary Tract Cancers
por: Boilève, Alice, et al.
Publicado: (2021)

Synergizing liver systemic treatments with interventional oncology: friend or foe?
por: Jost, Raphaël, et al.
Publicado: (2022)

Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?
por: Jang, Albert, et al.
Publicado: (2021)

Immunotherapy after liver transplantation: Where are we now?
por: Au, Kin Pan, et al.
Publicado: (2021)

Oral Immunotherapy in Food Allergy: Where Are We Now?
por: Özdemir, Pınar Gökmirza, et al.
Publicado: (2023)

Peptide-based immunotherapy in lupus: Where are we now?
por: P. Singh, Ram, et al.
Publicado: (2023)

Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
por: Tovoli, Francesco, et al.
Publicado: (2020)

Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?
por: Dixon-Douglas, Julia, et al.
Publicado: (2023)

Where are we now?
Publicado: (1977)

Voices: Where are they now?
Publicado: (2023)

Where are we now and where are we headed?
por: Langan, Ewan A.
Publicado: (2023)

Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer
por: Cartry, Jérôme, et al.
Publicado: (2023)

Bisphenol A: Where to Now?
por: Bucher, John R.
Publicado: (2009)

Social radiology: Where to now?
por: Ho, ELM
Publicado: (2012)

NIPPV: Where Are We Now?
por: Fakharian, Atefeh, et al.
Publicado: (2013)

Onchodermatitis: Where Are We Now?
por: Murdoch, Michele E.
Publicado: (2018)

Melanoma Immunotherapy and Precision Medicine in the Era of Tumor Micro-Tissue Engineering: Where Are We Now and Where Are We Going?
por: Varrone, Francesca, et al.
Publicado: (2021)

Where is Archives of Plastic Surgery Now? And Where is It Heading?
por: Kim, Jeong Tae
Publicado: (2014)

Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial – PACHA-01 (NCT02494973)
por: Goéré, Diane, et al.
Publicado: (2018)

Predictive Biomarkers of Bacillus Calmette-Guérin Immunotherapy Response in Bladder Cancer: Where Are We Now?
por: Lima, Luís, et al.
Publicado: (2012)

Phenotypic and molecular basis for genetic variation in jelly palms (Butia sp.): where are we now and where are we headed to?
por: Cidón, Camila Fritzen, et al.
Publicado: (2023)

Mechanism of diabetic neuropathy: Where are we now and where to go?
por: Yagihashi, Soroku, et al.
Publicado: (2011)

Advances in digital CBT: where are we now, and where next?
por: Thew, Graham R., et al.
Publicado: (2022)

AI in medicine: Where are we now and where are we going?
por: Shandhi, Md Mobashir Hasan, et al.
Publicado: (2022)

Intrahepatic Cholangiocarcinoma—Where Are We Now and Where Are We Going to?
por: Wasilewicz, Michał P., et al.
Publicado: (2023)

Aromatase inhibitors--where are we now?
por: Miller, W. R.
Publicado: (1996)

Depression research: where are we now?
por: Lee, Saebom, et al.
Publicado: (2010)

Personal workstations: Where are we now?
por: Willers, Ian Malcolm
Publicado: (1982)

Human papillomavirus vaccination: where to now?
por: Garland, S M
Publicado: (2011)

Personal genomics: Where are we now?
por: Angrist, Misha
Publicado: (2016)

9. GFR - Where are We Now?
por: Delanghe, Joris R.
Publicado: (2009)

Calcaneal fractures: Where are we now?
por: Razik, Aisha, et al.
Publicado: (2017)

Intracranial Atherosclerosis: Where Are We Now?
por: Kim, Jong S.
Publicado: (2017)

Mindfulness in psychiatry – where are we now?
por: Groves, Paramabandhu
Publicado: (2016)

MHC Restriction: Where Are We Now?
por: Zareie, Pirooz, et al.
Publicado: (2020)

Where to Now for One Health and Ecohealth?
por: Mi, Emma, et al.
Publicado: (2016)

Microbiota and Obesity: Where Are We Now?
por: Ballini, Andrea, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_oajf7m6v5hp50calcrikd3osak